[Treatment of PT1 tumors of the bladder using transurethral resection and intravesical immunotherapy].
Twenty-six patients with a PT1 urothelial bladder tumour were treated by transurethral resection and endovesical BCG. The authors compared previously untreated patients with patients with a history of bladder tumour present for an average of 4.6 years. The results of this study show that 72% of bladders in the first group were preserved compared with 53% in the second group. 45% of patients in whom the tumour invaded the superficial lamina propria developed a recurrence compared with 100% of tumours with invasion of the deep lamina propria. 25% of patients who developed a recurrence died in the course of this study.
Bertault
D
D
Service d'Urologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre.
Benoit
G
G
Vieillefond
A
A
Ribaud
P
P
Bensadoun
H
H
Jardin
A
A
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015653:Cystectomy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011468:Prostatectomy; D001743:Urinary Bladder / Q000601:surgery*; D001749:Urinary Bladder Neoplasms / Q000601:surgery* / Q000628:therapy
D001500:BCG Vaccine
Traitement des tumeurs de vessie PT1 par résection trans-urétrale et immunothérapie endo-vésicale.